Braun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Braun Stacey Associates Inc. trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 100,022 shares of the biotechnology company's stock after selling 2,990 shares during the period. Braun Stacey Associates Inc. owned 0.10% of Sarepta Therapeutics worth $12,162,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Simplify Asset Management Inc. lifted its stake in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock valued at $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Geode Capital Management LLC raised its position in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC raised its position in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Larson Financial Group LLC raised its position in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Finally, abrdn plc raised its position in Sarepta Therapeutics by 30.7% during the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company's stock worth $53,935,000 after purchasing an additional 101,253 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SRPT shares. HC Wainwright reaffirmed a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Evercore ISI lowered their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. Finally, Guggenheim raised their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $176.77.

Sarepta Therapeutics Stock Down 2.0 %

Shares of SRPT traded down $2.13 during trading hours on Friday, hitting $106.28. The stock had a trading volume of 709,268 shares, compared to its average volume of 811,414. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a 50 day simple moving average of $117.54 and a 200-day simple moving average of $123.61. The firm has a market capitalization of $10.15 billion, a P/E ratio of 85.02 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 1-year low of $101.15 and a 1-year high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company's stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.